Citigroup Inc. set a GBX 6,000 ($77.49) price target on AstraZeneca plc (LON:AZN) in a research report released on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities analysts also recently commented on AZN. UBS AG set a GBX 5,150 ($66.51) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Tuesday, June 27th. Shore Capital restated a hold rating on shares of AstraZeneca plc in a research note on Monday, September 11th. J P Morgan Chase & Co set a GBX 4,200 ($54.24) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Wednesday, August 9th. Jefferies Group LLC upped their price target on shares of AstraZeneca plc from GBX 4,350 ($56.18) to GBX 4,800 ($61.99) and gave the company a hold rating in a research note on Monday, September 11th. Finally, Bryan, Garnier & Co upgraded shares of AstraZeneca plc to a buy rating and upped their price target for the company from GBX 4,700 ($60.70) to GBX 5,380 ($69.48) in a research note on Monday, September 11th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of GBX 5,022.91 ($64.87).
AstraZeneca plc (LON:AZN) opened at 4719.50 on Wednesday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The company’s market capitalization is GBX 59.75 billion. The stock’s 50 day moving average is GBX 4,556.15 and its 200-day moving average is GBX 4,880.61.
The company also recently announced a dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, August 10th were given a dividend of GBX 68.90 ($0.89) per share. This represents a yield of 1.35%. The ex-dividend date was Thursday, August 10th.
In other news, insider Nazneen Rahman bought 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.